Search - tctmd.com

Displaying 1 - 20 of 24

Sort: Relevancy | Date

MICHELLE Published: Low-Dose Rivaroxaban Cuts VTE Risk After COVID-19 Admission

News Daily News

MICHELLE Published: Low-Dose Rivaroxaban Cuts VTE Risk After COVID-19 Admission

December 29, 2021

AHA’s 2021 Top Picks: Headway Continues to Be Made Against CVD

News Daily News

AHA’s 2021 Top Picks: Headway Continues to Be Made Against CVD

December 28, 2021

Apixaban Appears Safer, More Effective Than Rivaroxaban in Medicare Study

News Daily News

Apixaban Appears Safer, More Effective Than Rivaroxaban in Medicare Study

December 27, 2021

FDA Approves Two Additional Indications for Rivaroxaban in Children

News Daily News

FDA Approves Two Additional Indications for Rivaroxaban in Children

December 21, 2021

Select COVID-19 Patients May Benefit From Postdischarge Anticoagulation

News Daily News

Select COVID-19 Patients May Benefit From Postdischarge Anticoagulation

November 25, 2021

November 2021 News Roundup

News Opinion CV Team Dispatch

November 2021 News Roundup

November 01, 2021

USPSTF at Last Takes Tougher Stance on Aspirin in Primary Prevention

News Daily News

USPSTF at Last Takes Tougher Stance on Aspirin in Primary Prevention

October 15, 2021

Rivaroxaban Again Linked to More Bleeding vs Other DOACs

News Daily News

Rivaroxaban Again Linked to More Bleeding vs Other DOACs

October 11, 2021

Finerenone Reduces CV Outcomes in Patients With Early CKD, Diabetes: FIGARO-DKD

News Conference News ESC 2021

Finerenone Reduces CV Outcomes in Patients With Early CKD, Diabetes: FIGARO-DKD

Michael O'Riordan

August 28, 2021

ESC 2021: Trials, Guidelines, and Channel Surfing at This Year’s Virtual Congress

News Opinion Editor's Corner ESC 2021

ESC 2021: Trials, Guidelines, and Channel Surfing at This Year’s Virtual Congress

August 19, 2021

Rivaroxaban Safe, Effective in Renal Disease: VOYAGER PAD

News Daily News

Rivaroxaban Safe, Effective in Renal Disease: VOYAGER PAD

August 10, 2021

Apixaban May Be Best DOAC for Frail, Older Patients With AF

News Daily News

Apixaban May Be Best DOAC for Frail, Older Patients With AF

July 19, 2021

FDA Approves Finerenone for Adults With CKD and Type 2 Diabetes

News Daily News

FDA Approves Finerenone for Adults With CKD and Type 2 Diabetes

Yael L. Maxwell

July 09, 2021

Rivaroxaban Helps Prevent More Events Than Aspirin Alone After Leg Interventions

News Conference News ACC 2021

Rivaroxaban Helps Prevent More Events Than Aspirin Alone After Leg Interventions

May 21, 2021

ACTION: Full-Dose Rivaroxaban Doesn’t Help in Hospitalized COVID-19

News Conference News ACC 2021

ACTION: Full-Dose Rivaroxaban Doesn’t Help in Hospitalized COVID-19

May 17, 2021

ATLANTIS: Apixaban Has No Benefit Over Standard of Care Post-TAVI

News Conference News ACC 2021

ATLANTIS: Apixaban Has No Benefit Over Standard of Care Post-TAVI

Yael L. Maxwell

May 15, 2021

Finerenone Cuts CV Events in CKD Patients With Diabetes: FIGARO-DKD

News Daily News

Finerenone Cuts CV Events in CKD Patients With Diabetes: FIGARO-DKD

Michael O'Riordan

May 11, 2021

Observational Study Supports Continuing Oral Anticoagulation During PCI

News Daily News

Observational Study Supports Continuing Oral Anticoagulation During PCI

Michael O'Riordan

April 06, 2021

DOACs Safe, Effective in Subset of Valvular AF Patients

News Daily News

DOACs Safe, Effective in Subset of Valvular AF Patients

March 31, 2021

Nonstenotic Intracranial Plaque: An Underrecognized Source of Embolic Stroke

News Daily News

Nonstenotic Intracranial Plaque: An Underrecognized Source of Embolic Stroke

February 10, 2021

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.